Expert Opinion on the Use of Vildagliptin in Indian Patients with Diabetes Mellitus
Manjula S *
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
Krishna Kumar M
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Background: Diabetes mellitus is a prevalent disease, and its burden has increased over the years which is going to cross 134 million cases by 2045, despite the available treatments. This study was carried out to understand the prescribing behaviours in the management of diabetes.
Methodology: In this cross-sectional study conducted from June 2022 to December 2022, a questionnaire was administered to clinicians focused on diabetes prevalence, symptoms, causes, clinical characteristics, and the utilization of different antidiabetic medications. The data collected was analysed using descriptive statistics.
Results: Around 353 clinicians responded with the majority from Delhi (8.8%). The most commonly preferred first-line drug is metformin (46.5%). Vildagliptin (89%) is the most preferred drug out of the DPP-4 inhibitors that is added to metformin to achieve glycaemic control. Dapagliflozin (87%) is the most preferred SGLT-2 inhibitor. It was seen that 59.2% opted for DPP-4 inhibitor and SGLT-2 inhibitor FDC in 25 to 50% of their diabetic patients. If affordability was not an issue most clinicians (44.2%) preferred vildagliptin, dapagliflozin, and metformin FDC. Insulin usage declined with 38.8% reporting that they used insulin in only 11 to 15% of their diabetic patient pool and 71.4 % reported hypertension as the most common comorbidity with diabetes.
Conclusion: This study gives a comprehensive view of the perspectives of the medical community with respect to evidence-based change in management trends which will help make strategies to improve patient outcomes. It also sheds light on factors clinicians consider to choose treatment options. One criterion that is as important as efficacy and safety is affordability.
Keywords: Glycaemic control, clinician’s perspective, affordability, vildagliptin, dapagliflozin, metformin
How to Cite
Downloads
References
Sapra A, Bhandari P. Diabetes – Stat Pearls - NCBI Bookshelf with the Internet]. StatPearls Publishing; 2023. [cited 2023 Nov 23]. Availablefrom:https://www.ncbi.nlm.nih.gov/books/NBK551501/
Diabetes. World Health Organization; 2023. [cited 2023 Nov 23]. Available from:https://www.who.int/health-topics/diabetes#tab=tab_1
Mohan V, Pradeepa R. Epidemiology of type 2 diabetes in India. Indian Journal of Ophthalmology. 2021;69(11):2932.
Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology. 2016;12(10):566–92.
Pourhabibi N, Mohebbi B, Sadeghi R, Shakibazadeh E, Sanjari M, Tol A et al. Factors associated with treatment adherence to treatment among in patients with type 2 diabetes in Iran: A cross-sectional study. Frontiers in Public Health. 2022;10:976888.
Murayama H, Imai K, Odawara M. Factors influencing the prescribing preferences of physicians for drug-naive patients with type 2 diabetes mellitus in the real-world setting in Japan: Insight from a web survey. Diabetes Therapy. 2018;9(3): 1185–99.
American Diabetes Association releases 2023 standards of care in diabetes to guide prevention, diagnosis, and treatment for people living with diabetes; 2022. [cited 2023 Nov 24]. Availablefrom:https://www2.diabetes.org/newsroom/press-releases/2022/american-diabetes-association-2023-standards-care-diabetes-guide-for-prevention-diagnosis-treatment-people-living-with-diabetes
Misra A, Gopalan H, Jayawardena R, Hills AP, Soares M, Reza‐Albarrán AA, Ramaiya KL. Diabetes in developing countries. Journal of Diabetes. 2019; 11(7):522-39.
Sriram S, Khan MM. Effect of health insurance program for the poor on out-of-pocket inpatient care cost in India: Evidence from a nationally representative cross-sectional survey. BMC Health Services Research. 2020;20(1):839.
Eyth E, Naik R. Hemoglobin A1C - statpearls - NCBI bookshelf. StatPearls Publishing; 2023. [cited 2023 Nov 24]. Availablefrom:https://www.ncbi.nlm.nih.gov/books/NBK549816/
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al. Classification and diagnosis of diabetes: Standards of care in diabetes—2023. Diabetes Care. 2022;46(Suppl 1):S19-S40.
Agarwal A, Jadhav P, Deshmukh Y. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. Journal of Basic and Clinical Pharmacy. 2014;5(3):79.
Singh A. Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Indian Journal of Endocrinology and Metabolism. 2014; 18(5):617.
Ionova T, Nikitina T, Kurbatova K, Rodionova A. Benefits and risks of vildagliptin/metformin versus sulphonylureas/metformin combination therapy in type 2 diabetes mellitus (T2DM) from patient’s perspective: Real-World Data. Value in Health. 2015;18(7):A335–A766.
Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A et al. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technology & amp; Therapeutics. 2012; 14(6):475–84.
Schweizer A. Combination treatment in the management of type 2 diabetes: Focus on vildagliptin and metformin as a single tablet. Vascular Health and Risk Management. 2008;4:481–92.
Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations. Kidney International Reports. 2022; 7(7):1463–76.
Jiang Y, Yang P, Fu L, Sun L, Shen W, Wu Q. Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2022;13:802992.
Min SH, Yoon J-H, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: A systematic review with meta- analysis. Scientific Reports. 2018; 8(1):4466.
Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32(suppl_2):S253-9.
Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Canadian Journal of Cardiology. 2018; 34(5):575–84.
Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites: the San Antonio Heart Study. American Journal of Epidemiology. 1990;131(3):423-33.